Literature DB >> 18475361

Penetration of piperacillin/tazobactam into gynecologic tissues following a single loading dose prior to hysterectomy.

W F O'Brien1, S George.   

Abstract

OBJECTIVE: This study was undertaken to determine plasma and pelvic tissue concentrations of piperacillin/tazobactam following a single intravenous administration.
METHODS: Plasma and tissue samples were obtained following administration of 3 g of piperacillin and 0.375 g of tazobactam. Concentrations of these agents were determined by chromatography.
RESULTS: Plasma concentrations (mean +/-SD) for piperacillin/tazobactam were 208 +/- 87/27 +/- 8 and 95 +/- 53/14 +/- 2, respectively, at 30 and 60 min after the start of the infusion. The 8:1 ratio between piperacillin and tazobactam in plasma remained constant for up to 96 min. Tissue concentrations yielded a broader range, but each agent achieved significant penetration in each of the tissues studied.
CONCLUSIONS: Piperacillin/tazobactam demonstrates favorable penetration in female genital tract tissues and Should be considered a potentially effective agent for female pelvic infections.

Entities:  

Year:  1994        PMID: 18475361      PMCID: PMC2364356          DOI: 10.1155/S1064744994000347

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  8 in total

1.  Susceptibility of female pelvic pathogens to oral antibiotic agents in patients who develop postpartum endometritis.

Authors:  M G Martens; S Faro; M Maccato; G Riddle; H A Hammill
Journal:  Am J Obstet Gynecol       Date:  1991-05       Impact factor: 8.661

Review 2.  Patient costs for prophylaxis and treatment of obstetric and gynecologic surgical infections.

Authors:  G E Stein
Journal:  Am J Obstet Gynecol       Date:  1991-05       Impact factor: 8.661

3.  Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.

Authors:  S Gatermann; R Marre
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

Review 4.  Pelvic inflammatory disease. Key treatment issues and options.

Authors:  H B Peterson; C K Walker; J G Kahn; A E Washington; D A Eschenbach; S Faro
Journal:  JAMA       Date:  1991-11-13       Impact factor: 56.272

5.  High-performance liquid chromatographic determination of a new beta-lactamase inhibitor and its metabolite in combination therapy with piperacillin in biological materials.

Authors:  T Marunaka; M Maniwa; E Matsushima; Y Minami
Journal:  J Chromatogr       Date:  1988-09-23

6.  Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography.

Authors:  A P Ocampo; K D Hoyt; N Wadgaonkar; A H Carver; C V Puglisi
Journal:  J Chromatogr       Date:  1989-11-10

7.  Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin.

Authors:  R Wise; M Logan; M Cooper; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

8.  A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.

Authors:  A E Eklund; C E Nord
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.